Abstract
Cell cycle checkpoints ensure genome integrity and are frequently compromised in human cancers. A therapeutic strategy being explored takes advantage of checkpoint defects in p53-deficient tumors in order to sensitize them to DNA-damaging agents by eliminating Chk1-mediated checkpoint responses. Using mouse models, we demonstrated that p21 is a key determinant of how cells respond to the combination of DNA damage and Chk1 inhibition (combination therapy) in normal cells as well as in tumors. Loss of p21 sensitized normal cells to the combination therapy much more than did p53 loss and the enhanced lethality was partially blocked by CDK inhibition. In addition, basal pools of p21 (p53 independent) provided p53 null cells with protection from the combination therapy. Our results uncover a novel p53-independent function for p21 in protecting cells from the lethal effects of DNA damage followed by Chk1 inhibition. As p21 levels are low in a significant fraction of colorectal tumors, they are predicted to be particularly sensitive to the combination therapy. Results reported in this study support this prediction.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998; 282: 1497–1501.
Shimuta K, Nakajo N, Uto K, Hayano Y, Okazaki K, Sagata N . Chk1 is activated transiently and targets Cdc25A for degradation at the Xenopus midblastula transition. EMBO J 2002; 21: 3694–3703.
Sorensen CS, Syluasen RG, Falck J, Schroeder T, Ronnstrand L, Khanna KK et al. Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A. Cancer Cell 2003; 3: 247–258.
Zhao H, Watkins JL, Piwnica-Worms H . Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints. Proc Natl Acad Sci USA 2002; 99: 14795–14800.
Falck J, Mailand N, Syljuasen RG, Bartek J, Lukas J . The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 2001; 410: 842–847.
Goloudina A, Yamaguchi H, Chervyakova DB, Appella E, Fornace Jr AJ, Bulavin DV . Regulation of human Cdc25A stability by serine 75 phosphorylation is not sufficient to activate a S-phase checkpoint. Cell Cycle 2003; 2: 473–478.
Hassepass I, Voit R, Hoffmann I . Phosphorylation at serine-75 is required for UV-mediated degradation of human Cdc25A phosphatase at the S-phase checkpoint. J Biol Chem 2003; 278: 29824–29829.
Ma CX, Janetka JW, Piwnica-Worms H . Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol Med 2010; 17: 88–96.
Bunch RT, Eastman A . Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2 checkpoint inhibitor. Clin Cancer Res 1996; 2: 791–797.
Wang O, Fan S, Eastman A, Worland PJ, Sausville EA, O’Conner PM . UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst 1996; 88: 956–965.
Levesque AA, Eastman A . p53-based cancer therapies: is defective p53 the Achilles heel of the tumor? Carcinogenesis 2007; 28: 13–20.
Levesque AA, Fanous AA, Poh A, Eastman A . Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest. Mol Cancer Ther 2008; 7: 252–262.
Zabludoff SD, Deng C, Grondine MR, Sheehy AM, Ashwell S, Caleb BL et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther 2008; 7: 2955–2966.
Taylor WR, Stark GR . Regulation of the G2/M transition by p53. Oncogene 2001; 20: 1803–1815.
Abbas T, Dutta A . p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 2009; 9: 400–414.
Ferguson AT, Evron E, Umbricht CB, Pandita TK, Chan TA, Hermeking H et al. High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. Proc Natl Acad Sci USA 2000; 97: 6049–6054.
Fracasso PM, Williams KJ, Chen RC, Picus J, Ma CX, Ellis MJ et al. A phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies. Cancer Chemother Pharmacol 2011; 67: 1225–1237.
Kohn EA, Ruth ND, Brown MK, Livingstone M, Eastman A . Abrogation of the S phase DNA damage checkpoint results in S phase progression or premature mitosis depending on the concentration of 7-hydroxystaurosporine and the kinetics of Cdc25C activation. J Biol Chem 2002; 277: 26553–26564.
Sedelnikova OA, Pilch DR, Redon C, Bonner WM . Histone H2AX in DNA damage and repair. Cancer Biol Ther 2003; 2: 233–235.
Lam MH, Liu Q, Elledge SJ, Rosen JM . Chk1 is haploinsufficient for multiple functions critical to tumor suppression. Cancer Cell 2004; 6: 45–59.
Perez RP, Lewis LD, Beelen AP, Olszanski AJ, Johnston N, Rhodes CH et al. Modulation of cell cycle progression in human tumors: a pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850). Clin Cancer Res 2006; 12: 7079–7085.
Xu B, Kim S-T, Kastan MB . Involvement of Brca1 in S-phase and G2-phase checkpoints after ionizing radiation. Mol Cell Biol 2001; 21: 3445–3450.
Tapia C, Kutzner H, Mentzel T, Savic S, Baumhoer D, Glatz K . Two mitosis-specific antibodies, MPM-2 and phospho-histone H3 (Ser28), allow rapid and precise determination of mitotic activity. Am J Surg Pathol 2006; 30: 83–89.
Parker LL, Piwnica-Worms H . Inactivation of the p34cdc2-cyclin B complex by the human wee1 tyrosine kinase. Science 1992; 257: 1955–1957.
Goga A, Yang D, Tward AD, Morgan DO, Bishop JM . Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nat Med 2007; 13: 820–827.
Cespedes MV, Espina C, Garcia-Cabezas MA, Trias M, Boluda A, Gomez del Pulgar MT et al. Orthotopic microinjection of human colon cancer cells in nude mice induces tumor foci in all clinically relevant metastatic sites. Am J Pathol 2007; 170: 1077–1085.
Waldman T, Kinzler KW, Vogelstein B . p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 1995; 55: 5187–5190.
Eastman A . Cell cycle checkpoints and their impact on anticancer therapeutic strategies. J Cell Biochem 2004; 91: 223–231.
Rodriguez R, Meuth M . Chk1 and p21 cooperate to prevent apoptosis during DNA replication fork stress. Mol Biol Cell 2006; 17: 402–412.
Luo Y, Hurwitz J, Massague J . Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1. Nature 1995; 375: 159–161.
Besson A, Dowdy SF, Roberts JM . CDK inhibitors: cell cycle regulators and beyond. Dev Cell 2008; 14: 159–169.
Sherr CJ, Roberts JM . CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 13: 1501–1512.
Kohn EA, Yoo CJ, Eastman A . The protein kinase C inhibitor Go6976 is a potent inhibitor of DNA damage-induced S and G2 cell cycle checkpoints. Cancer Res 2003; 63: 31–35.
Tse AN, Rendahl KG, Sheikh T, Cheema H, Aardalen K, Embry M et al. CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo. Clin Cancer Res 2007; 13 (2 Pt 1): 591–602.
Fikaris AJ, Lewis AE, Abulaiti A, Tsygankova OM, Meinkoth JL . Ras triggers ataxia-telangiectasia-mutated and Rad-3-related activation and apoptosis through sustained mitogenic signaling. J Biol Chem 2006; 281: 34759–34767.
Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006; 444: 633–637.
Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, Luise C et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006; 444: 638–642.
Gilad O, Nabet BY, Ragland RL, Schoppy DW, Smith KD, Durham AC et al. Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner. Cancer Res 2010; 70: 9693–9702.
Raynaud FI, Fischer PM, Nutley BP, Goddard PM, Lane DP, Workman P . Cassette dosing pharmacokinetics of a library of 2,6,9-trisubstituted purine cyclin-dependent kinase 2 inhibitors prepared by parallel synthesis. Mol Cancer Ther 2004; 3: 353–362.
Acknowledgements
We thank Dr B Vogelstein for providing the HCT116 cell lines. This study was supported in part by NIH GM047017, the KOMEN Foundation and P50 CA94056 to the Molecular Imaging Center at Washington University. HP-W is a Research Professor of the American Cancer Society.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Oncogene website
Supplementary information
Rights and permissions
About this article
Cite this article
Origanti, S., Cai, Sr., Munir, A. et al. Synthetic lethality of Chk1 inhibition combined with p53 and/or p21 loss during a DNA damage response in normal and tumor cells. Oncogene 32, 577–588 (2013). https://doi.org/10.1038/onc.2012.84
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2012.84
Keywords
This article is cited by
-
Sensitization of colorectal cancer to irinotecan therapy by PARP inhibitor rucaparib
Investigational New Drugs (2019)
-
The cell cycle checkpoint inhibitors in the treatment of leukemias
Journal of Hematology & Oncology (2017)
-
Molecularly targeted therapies for p53-mutant cancers
Cellular and Molecular Life Sciences (2017)
-
Translational and clinical implications of the genetic landscape of prostate cancer
Nature Reviews Clinical Oncology (2016)
-
HUS1 regulates in vivo responses to genotoxic chemotherapies
Oncogene (2016)